A new pharmacodynamic approach to study antibiotic combinations against enterococci in vivo: Application to ampicillin plus ceftriaxone
Open Access
- 8 December 2020
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (12) , e0243365
Abstract
The combination of ampicillin (AMP) and ceftriaxone (CRO) is considered synergistic againstEnterococcus faecalisbased onin vitrotests and the rabbit endocarditis model, however,in vitroassays are limited by the use of fixed antibiotic concentrations and the rabbit model by poor bacterial growth, high variability, and the use of point dose-effect estimations, that may lead to inaccurate assessment of antibiotic combinations and hinder optimal translation. Here, we tested AMP+CRO against two strains ofE.faecalisand one ofE.faeciumin an optimized mouse thigh infection model that yields high bacterial growth and allows to define the complete dose-response relationship. By fitting Hill’s sigmoid model and estimating the parameters maximal effect (Emax) and effective dose 50 (ED50), the following interactions were defined: synergism (Emaxincrease ≥2 log10CFU/g), antagonism (Emaxreduction ≥1 log10CFU/g) and potentiation (ED50reduction ≥50% without changes in Emax). AMP monotherapy was effective against the three strains, yielding valid dose-response curves in terms of dose and the indexfT>MIC. CRO monotherapy showed no effect. The combination AMP+CRO againstE.faecalisled to potentiation (59–81% ED50reduction) and not synergism (no changes in Emax). AgainstE.faecium, the combination was indifferent. The optimized mouse infection model allowed to obtain the complete dose-response curve of AMP+CRO and to define its interaction based on pharmacodynamic parameter changes. Integrating these results with the pharmacokinetics will allow to derive the PK/PD index bound to the activity of the combination, essential for proper translation to the clinic.Keywords
This publication has 33 references indexed in Scilit:
- Novel Modeling Framework To Guide Design of Optimal Dosing Strategies for β-Lactamase InhibitorsAntimicrobial Agents and Chemotherapy, 2012
- Management of multidrug-resistant enterococcal infectionsClinical Microbiology and Infection, 2010
- In vitro Antimicrobial Activity of Ampicillin-Ceftriaxone and Ampicillin-Ertapenem Combinations Against Clinical Isolates of Enterococcus faecalis with High Levels of Aminoglycoside ResistanceThe Open Microbiology Journal, 2008
- Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice AnymoreClinical Infectious Diseases, 2007
- Efficacy of ampicillin combined with ceftriaxone and gentamicin in the treatment of experimental endocarditis due to Enterococcus faecalis with no high-level resistance to aminoglycosidesJournal of Antimicrobial Chemotherapy, 2003
- The Thin Line Between Gut Commensal and PathogenScience, 2003
- State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and MenClinical Infectious Diseases, 1998
- Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalisAntimicrobial Agents and Chemotherapy, 1995
- Comparison of the antibacterial efficacies of ampicillin and ciprofloxacin against experimental infections with Listeria monocytogenes in hydrocortisone-treated miceAntimicrobial Agents and Chemotherapy, 1992
- Triple-Combination Penicillin-Vancomycin-Gentamicin for Experimental Endocarditis Caused by a Moderately Penicillin- and Highly GlycopeptideResistant Isolate of Enterococcus faeciumThe Journal of Infectious Diseases, 1991